Gene:
MAPK8
mitogen-activated protein kinase 8

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  JUN N-terminal kinase; PRKM8
Alternate Symbols:  JNK; JNK1; SAPK1
PharmGKB Accession Id: PA283

Details

Cytogenetic Location: chr10 : q11.22 - q11.22
GP mRNA Boundary: chr10 : 49514682 - 49647403
GP Gene Boundary: chr10 : 49504682 - 49650403
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.
  1. Tacrolimus/Cyclosporine Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of tacrolimus and cyclosporine, as well as the candidate genes believed to interact with the two drugs.
  1. VEGF Signaling Pathway
    Model endothelial cell displaying genes of the VEGF signalling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib and cilengitide are known to act.

Curated Information ?

Curated Information ?

Evidence Drug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
insulin-glargine
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
sorafenib

Curated Information ?

Publications related to MAPK8: 4

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diverse genome-wide association studies associate the IL12/IL23 pathway with Crohn Disease. American journal of human genetics. 2009. Wang Kai, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science (New York, N.Y.). 2008. Sabio Guadalupe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research. 2004. Wilhelm Scott M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. The Journal of biological chemistry. 1997. Kroll J, et al. PubMed

LinkOuts

NCBI Gene:
5599
OMIM:
601158
UCSC Genome Browser:
NM_002750
RefSeq RNA:
NM_002750
NM_139046
NM_139047
NM_139049
RefSeq Protein:
NP_002741
NP_620634
NP_620635
NP_620637
RefSeq DNA:
NT_030059
UniProtKB:
A1L4K2_HUMAN (A1L4K2)
MK08_HUMAN (P45983)
Ensembl:
ENSG00000107643
GenAtlas:
MAPK8
GeneCard:
MAPK8
MutDB:
MAPK8
ALFRED:
LO003424N
HuGE:
MAPK8
Comparative Toxicogenomics Database:
5599
ModBase:
P45983
HumanCyc Gene:
HS03015
HGNC:
6881

Common Searches